|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000143570 |
Summary for SLC39A1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000143570 | Gene symbol | SLC39A1 |
| Gene name | solute carrier family 39 member 1 | |
| HGNC | 12876 | |
| Entrez ID | 27173 | |
| Gene type | protein_coding | |
| Synonyms | SLC39A1|ZIP1 | |
| UniProtAcc | Q9NY26 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for SLC39A1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC39A1 | 8.76e+03 | 1.24e+00 | 2.89e-01 | 4.30e+00 | 1.72e-05 | 9.14e-05 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for SLC39A1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for SLC39A1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg09895920 | chr1:153968710 | CGI:chr1:153967167-153967504 | promoter | 5.89e-01 | 4.87e-01 | 2.68e+00 | 7.36e-03 | 1.52e-02 | 1.02e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg09895920 | chr1:153968710 | CGI:chr1:153967167-153967504 | promoter | 1.72e-01 | 4.58e-02 | 5.45e+00 | 4.95e-08 | 2.74e-07 | 1.26e-01 |
| LUSC | cg25064552 | chr1:153966383 | CGI:chr1:153967167-153967504 | promoter,gene body | 7.00e-01 | 9.34e-01 | -3.88e+00 | 1.06e-04 | 7.14e-04 | -2.33e-01 |
| LUSC | cg09895920 | chr1:153968710 | CGI:chr1:153967167-153967504 | promoter | 4.12e-01 | 7.77e-02 | 3.31e+00 | 9.29e-04 | 2.47e-03 | 3.35e-01 |
| COAD | cg09895920 | chr1:153968710 | CGI:chr1:153967167-153967504 | promoter | 2.98e-01 | 9.14e-02 | 2.26e+00 | 2.41e-02 | 2.85e-02 | 2.06e-01 |
| BLCA | cg25064552 | chr1:153966383 | CGI:chr1:153967167-153967504 | promoter,gene body | 6.68e-01 | 9.07e-01 | -3.47e+00 | 5.20e-04 | 1.37e-03 | -2.39e-01 |
| LIHC | cg09895920 | chr1:153968710 | CGI:chr1:153967167-153967504 | promoter | 7.20e-01 | 5.55e-01 | 4.30e+00 | 1.70e-05 | 4.34e-05 | 1.66e-01 |
| ESCA | cg09895920 | chr1:153968710 | CGI:chr1:153967167-153967504 | promoter | 3.68e-01 | 7.70e-02 | 2.59e+00 | 9.57e-03 | 3.60e-02 | 2.91e-01 |
| CHOL | cg09895920 | chr1:153968710 | CGI:chr1:153967167-153967504 | promoter | 2.00e-01 | 7.91e-01 | -3.24e+00 | 1.18e-03 | 1.07e-02 | -5.91e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25064552 | chr1:153966383 | CGI:chr1:153967167-153967504 | promoter,gene body | 7.62e-01 | 9.39e-01 | -9.11e+00 | 7.88e-20 | 4.20e-19 | -1.77e-01 |
| KIRP | cg09895920 | chr1:153968710 | CGI:chr1:153967167-153967504 | promoter | 3.33e-01 | 8.75e-02 | 2.25e+00 | 2.46e-02 | 3.07e-02 | 2.45e-01 |
Top |
Exon skipping events with PSI in TCGA for SLC39A1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for SLC39A1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for SLC39A1 |
| TFs related to SLC39A1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BLCA | KLF7 | SLC39A1 | 3.95e+00 | 9.81e-01 | 2.46e+00 | 9.46e-04 | Male-biased |
| BRCA | PLAG1 | SLC39A1 | 2.26e+00 | 9.82e-04 | 4.20e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF28 | SLC39A1 | 2.14e+00 | 7.51e-04 | 4.16e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF331 | SLC39A1 | 2.31e+00 | 9.52e-04 | 4.26e+00 | 9.84e-01 | Female-biased |
| BRCA | ZNF333 | SLC39A1 | 2.62e+00 | 2.85e-03 | 4.22e+00 | 9.80e-01 | Female-biased |
| BRCA | ZNF793 | SLC39A1 | 2.71e+00 | 3.17e-03 | 4.27e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF891 | SLC39A1 | 2.12e+00 | 6.63e-04 | 4.18e+00 | 9.82e-01 | Female-biased |
| MESO | BPTF | SLC39A1 | 2.57e+00 | 4.67e-03 | 4.06e+00 | 9.82e-01 | Female-biased |
| MESO | FOXG1 | SLC39A1 | 1.23e+00 | 6.86e-05 | 3.79e+00 | 9.80e-01 | Female-biased |
| MESO | ZNF33B | SLC39A1 | 1.86e+00 | 2.21e-04 | 4.14e+00 | 9.88e-01 | Female-biased |
| MESO | ZNF570 | SLC39A1 | 1.13e+00 | 2.74e-05 | 3.94e+00 | 9.84e-01 | Female-biased |
| SLC39A1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for SLC39A1 |
| RBPs related to ES in SLC39A1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| SLC39A1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12751821 | chr1:157431562:T:A | - | 0.163837471706136 | 0.0199185457335004 | READ | Female-baised eQTL |
| rs6695707 | chr1:161022031:A:C | - | 0.206128695087029 | 0.0239025932167363 | KIRP | Female-baised eQTL |
| rs4845693 | chr1:154938781:C:T | - | 0.095127239782787 | 0.0487239679409487 | KIRP | Female-baised eQTL |
| rs9438040 | chr1:147885803:T:C | - | 0.142627463386574 | 0.0344907637972959 | LIHC | Female-baised eQTL |
| rs6680920 | chr1:160581296:A:G | - | -0.299701432798854 | 0.0222659923025414 | BLCA | Female-baised eQTL |
| rs2438181 | chr1:160595401:G:C | - | -0.297975465388647 | 0.0244043195279403 | BLCA | Female-baised eQTL |
| rs1149381 | chr1:160603996:G:T | - | -0.297975465388647 | 0.0244043195279403 | BLCA | Female-baised eQTL |
| rs7549676 | chr1:160591377:A:T | - | -0.295516745840565 | 0.0279301657073433 | BLCA | Female-baised eQTL |
| rs7413789 | chr1:160607462:C:T | - | -0.277026266752414 | 0.0318893640658582 | BLCA | Female-baised eQTL |
| rs12089980 | chr1:152459455:C:T | - | 0.0605141006801079 | 0.0273143154497586 | LUAD | Female-baised eQTL |
| rs58999833 | chr1:159947320:G:A | - | 0.0822110136517996 | 0.0469441024006855 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs16843784 | chr1:162711043:C:T | - | 0.125511840158426 | 0.0093555078466865 | LIHC | Male-baised eQTL |
| rs6695961 | chr1:162714569:T:C | - | -0.0696947874336444 | 0.0215837117388392 | LIHC | Male-baised eQTL |
| rs10799868 | chr1:162710700:T:C | - | -0.0694772031522957 | 0.0221445164213489 | LIHC | Male-baised eQTL |
| rs72702913 | chr1:158781481:A:G | - | -0.0727960795093534 | 0.00936504110184021 | COAD | Male-baised eQTL |
| rs12410802 | chr1:158837370:T:A | - | 0.0505363748869341 | 0.0353301730459753 | COAD | Male-baised eQTL |
| rs17698133 | chr1:158770915:A:G | - | -0.0540618775285852 | 0.0361777261593811 | COAD | Male-baised eQTL |
| rs2353995 | chr1:147455914:A:G | - | 0.0373550096837306 | 0.0403812752213685 | COAD | Male-baised eQTL |
| rs74128262 | chr1:152537494:C:G | - | 0.0869254905405975 | 0.0405427012950542 | COAD | Male-baised eQTL |
| rs6662656 | chr1:152537923:G:A | - | 0.0869254905405975 | 0.0405427012950542 | COAD | Male-baised eQTL |
| rs55692268 | chr1:152538662:G:A | - | 0.0869254905405975 | 0.0405427012950542 | COAD | Male-baised eQTL |
| rs857869 | chr1:158840522:C:T | - | 0.0386022185101934 | 0.0426781196018137 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000143570 |
| CpG Site: cg25064552 | |
| Position to Gene: gene,promoter | |
| Male Effect: - | |
| Female Effect: -0.240407383186936 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg25064552 | chr1:153966383 | gene,promoter | -0.240407383186936 | 5.29833130955456e-07 | -0.3708922521072524 | 9.777906050873733e-10 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of SLC39A1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000143570 | SLC39A1 | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
| ENSG00000143570 | SLC39A1 | C0035228 | Respiratory Hypersensitivity | 1 | CTD_human |
| ENSG00000143570 | SLC39A1 | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
